Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.

Authors: Marc Eid, Karl Semaan, Wanling Xie, Razane El Hajj Chehade, Liliana Ascione, David Maj, Martin Zarba, Connor Wells, Lori Wood, Cristina Suárez, Rana R. McKay, Guillermo De Velasco, Jeffrey Graham, Thomas Powles, Neeraj Agarwal, Aly-Khan A. Lalani, Ravindran Kanesvaran, Benoit Beuselinck, Toni K. Choueiri, Daniel Yick Chin Heng

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4555

Source: Full article

---

Abstract

4555